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Abstract. A Mobile Laboratory was developed for use primarily during the epidemic meningitis season in 
Burkina Faso. This report describes the Mobile Laboratory characteristics, its use to date, problems encountered 
and their resolution, and future directions. During 2004, the mobile laboratory intervention in three remote 
Burkina Faso districts experiencing meningitis epidemics led to more speciic case management and led 
directly to vaccination of one district. However, in a second district, the intervention occurred too late to 
allow vaccination. During 2006, the Mobile Laboratory was used to conduct an emergency carriage study that 
for the irst time occurred during the peak of a meningococcal serogroup A epidemic. This information is 
critical for the design of meningococcal conjugate vaccine schedules and vaccine approaches. During 2004-6, 
technicians in 11 district laboratories received training by Mobile Laboratory staff. Numerous problems with 
the initial prototype laboratory were identiied, namely that the solar power cells could not provide enough 
energy to the refrigerator and incubator to maintain appropriate temperatures and having a single integrated 
unit required use of a separate vehicle for specimen transport. A second laboratory was developed during 
2005-6 that used a generator or local energy source for power and that had a laboratory that could be detached 
from the vehicle. Currently the main limitation of the Mobile Laboratory is that it has not been integrated into 
routine Ministry of Health activities, limiting its use both during and between meningitis seasons. 
Keywords. diagnosis, epidemics, laboratory, meningitis, mobile laboratory, treatment, vaccine response. 
1 Introduction 
Until recently, acute bacterial meningitis epidemics in 
Sub-Saharan Africa were assumed to be due to Neisseria 
meningitidis (Nm) of serogroup A and epidemic response 
consisted of vaccination with bivalent A/C vaccine. The recent 
occurrence of epidemics due to Nm W135 and the availability 
of a limited supply of trivalent A/C/W135 polysaccharide (PS) 
vaccine have created a need for timely Nm serogroup informa-
tion to tailor vaccine response to the needs of speciic districts 
or regions (1–3). In Burkina Faso, the identiication of agents 
of acute bacterial meningitis usually relies on reference 
hospital laboratories. These laboratories, however, cover only 
30–40% of reported cases and meningitis epidemiology might 
differ considerably in more rural or remote areas. In addition 
to low surveillance coverage, countries like Burkina Faso 
often encounter shortages of reagents and consumable labora-
tory supplies. Lastly, developing countries have training needs 
for laboratory technicians as most technicians working in 
peripheral laboratories receive little formal training. To 
address these issues, AMP and the Burkina Faso Ministry 
of Health implemented a mobile laboratory designed to 
strengthen Ministry of Health capabilities to conirm bacterial 
meningitis etiology during epidemics, particularly in 
remote areas. 
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2 Mobile Laboratory design 
2.1 Mobile Laboratory 1 
During 2003, AMP conceived, designed, and tested in the ield 
a vehicle with microbiological laboratory facilities (Fig. 1). 
The laboratory unit was developed as a modiied, commercial 
four-wheel drive van (Renault “Kangoo” 4×4 diesel). Outitting 
was performed by the University of Münster, Germany. The 
Mobile Laboratory was outitted for performance of routine 
microbiology to allow provision of immediate feedback to 
local medical staff and District and National Ministry of 
Health decision-makers. It also had the capacity to transport 
specimens back to a reference laboratory in Bobo-Dioulasso 
or Ouagadougou for further analysis. 
To allow these functions, the Mobile Laboratory was 
air-conditioned and outitted with a refrigerator, hot plate, 
incubator, sink, microscope, and centrifuge (Fig. 2). Electric-
ity was provided by solar panels on the vehicle’s roof (Fig. 2). 
The refrigerator was installed for storage of reagents. The 
sink was installed to allow performance of Gram staining. 
 
 
 
 
 
The microscope allowed evaluation of Gram stain slides and 
determination of cerebrospinal luid white blood cell count. 
The incubator was set at 37°C and with an appropriate CO
2
 
concentration for bacterial culture. 
During actual implementation, several issues arose. The 
solar panels on the unit did not provide suficient electricity 
to maintain the temperature of the refrigerator (Fig. 3) and 
the incubator (Fig. 4) during the evening and night. The air 
conditioner of the selected vehicle did not perform well under 
ield conditions. Having the laboratory integrated into the 
vehicle meant that a separate vehicle was required to transport 
specimens and culture back to the reference laboratory. 
Lastly, the space available for laboratory technicians was not 
suficient for optimal work. 
 
Figure 1. Mobile Laboratory Prototype 1. Note that the unit is one 
piece and contains solar panels. 
Figure 2. Interior of Mobile Laboratory 1. 
Figure 4. Incubator temperature of the Mobile Laboratory 1 during 
ield conditions in Burkina Faso, 2004. 
Figure 3. Refrigerator temperature of the Mobile Laboratory 1 
during ield conditions in Burkina Faso, 2004. 
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2.2 Mobile Laboratory 2 
The Mobile Laboratory 2 was based on a Toyota Hilux 4x4, 
air-conditioned diesel vehicle (Figs. 5 and 6). We employed a 
detachable body that could remain on site, leaving the vehicle 
free to continue activities requiring mobility. The detachable 
body also fully isolates the driver’s cabin from the laboratory 
facilities, possibly decreasing the risk of contamination of 
specimens and increasing the safety of the driver and passen-
gers. We employed ixed electricity rather than solar panels, 
using a 2500 watt Honda diesel generator. Wiring allows for 
both 230V and 12V electricity. The incubator is a Binder 
GmbH CO
2
 incubator (Tuttlingen, Germany), which has a ca-
pacity of approximately 56–90 mm plates. Water is supplied 
via a 20 l canister with a similar 20 l canister for wastewater. 
3 Methods 
3.1 Mobile Laboratory 1 and outbreak response 
The Mobile Laboratory was send to three remote districts 
during 2004 that were experiencing epidemics. Once on site, 
Mobile Laboratory staff received cerebrospinal luid (CSF) 
specimens collected by local health facility personnel from 
suspected bacterial meningitis cases based on the WHO case 
deinition (4). The Mobile Laboratory staff then performed 
Gram staining, cytology, culture on chocolate agar and latex 
agglutination tests (Pastorex®). In addition to the Mobile 
Laboratory staff, two MOH technicians under the supervision 
of an MOH biologist accompanied the laboratory to the ield. 
A microbiologist from the Marseille-Pharo (France) WHO 
collaborating reference laboratory provided training for the 
technicians. 
Antibiotic resistance was determined in a reference labora-
tory using the disk-diffusion technique and measurement of 
minimal inhibitory concentrations by E-test (Solna, Sweden) 
(5). One aliquot of CSF for each case was shipped to Centre 
Muraz (Bobo-Dioulasso) for polymerase chain reaction (PCR) 
testing as previously described (3). Available results were 
provided immediately to the patient’s physician. A case was 
conirmed if latex agglutination, culture, or PCR yielded a 
positive result. External quality control was performed at the 
National Reference Laboratory in Ouagadougou. 
3.2 Mobile Laboratory 2 and technical assistance 
Based on the use of the irst prototype, a second Mobile 
Laboratory was built and placed in the ield during 2005 and 
2006. The Mobile Laboratory was not used for epidemic eval-
uation during this period. However, we describe here its use 
during a carriage study conducted in a rural area experiencing 
an epidemic and its use for the training of technicians in ive 
district laboratories. 
3.3 Ethical issues 
The Mobile Laboratory was used as part of the routine MOH 
emergency epidemic response. All tests performed were clin-
ically indicated or were part of the MOH epidemic surveil-
lance system. Under these circumstances of routine clinical 
management and public health surveillance, informed consent 
and institutional review board approval were neither sought 
nor obtained. 
4 Results 
4.1 Mobile Laboratory 1 and outbreak response 
4.1.1 Mobile Laboratory activities 
The Mobile Laboratory 1 was provided to the Burkina Faso 
Ministry of Health to intervene in districts in alert or epidemic 
for suspected acute bacterial meningitis. During 2004, three 
remote districts with poor access to laboratory facilities 
reported acute bacterial meningitis epidemics and were con-
sidered appropriate sites for the Mobile Laboratory. Nanoro 
passed the alert threshold during week 7 of the epidemic sea-
son and the epidemic threshold during week 12, and the 
Figure 5. Mobile Laboratory 2. Note the lack of ixed solar panels 
and the detachable laboratory unit. 
Figure 6. Interior of Mobile Laboratory 2.
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Mobile Laboratory 1 intervened during week 14 (Fig. 7). In 
Zabré, these events occurred during weeks 10, 12, and 14 and 
in Toma weeks 13, 14, and 16. The weekly reported incidences 
of suspected cases of acute bacterial meningitis in Nanoro, 
Zabré, and Toma the week before the intervention were 11, 
7.4 and 20 per 100,000 inhabitants. No collection and evalua-
tion of CSF specimens was performed and reported before the 
Mobile Laboratory interventions. In general, clinical staff re-
ported cases based on standard clinical criteria for suspected 
acute bacterial meningitis, but we did not have a mechanism 
for determining if this always occurred. 
Cerebrospinal luid specimens from 58 suspected cases 
were evaluated including from Nanoro (n=19), Zabré (n=26), 
and Toma (n=13) (median age, 2.5 years; 58% <5 years). Of 
these cases, 23 (40%) had a conirmed bacterial etiology (me-
dian age, 9.0 years; 43%<5 years). Etiology differed by loca-
tion with eight NmW135 and ive Streptococcus pneumoniae 
(Sp) in Nanoro, three NmA and one Sp in Zabré, and ive 
NmW135 and one Y/W135 (identiied by latex agglutination) 
in Toma. Meningococcal meningitis with coma and all pneu-
mococcal meningitis were treated with multi-day courses of 
intravenous ampicillin; the remaining Nm cases were treated 
with a single intramuscular dose of oily chloramphenicol. Of 
10 Nm and three Sp tested, all were sensitive to chloram-
phenicol, oxacillin and ceftriaxone. 
4.1.2 Vaccine interventions related to the Mobile 
Laboratory 1 intervention 
Before the Mobile Laboratory intervention, no specimens had 
been collected and analyzed from Nanoro and vaccination was 
delayed. Following the Mobile Laboratory conirmation of a 
meningococcal epidemic, and documentation of NmW135 as 
the primary agent, Nanoro residents aged 2–29 years received 
mass vaccination with trivalent Nm A/C/W135 polysaccharide 
vaccine during week 15 (postepidemic, the Burkina Faso 
Ministry of Health at two international meetings afirmed that 
the vaccine response was prompted by results from the Mobile 
Laboratory intervention). A total of 112,421 doses were 
administered during 3 to 8 April for an administrative vaccine 
coverage of 113% in the target population (Source: Burkina 
Faso Ministry of Health). No vaccine responses were organ-
ised in Zabré or Toma. In both districts, results were obtained 
after case counts had begun decreasing and in Zabré an A/C 
vaccination campaign had been conducted the previous year. 
4.1.3 Cost of the Mobile Laboratory 1 intervention 
We performed an assessment of the cost of the Mobile 
Laboratory for the intervention period. The Mobile Laboratory 
unit itself cost $44,200, including the cost of the vehicle 
($23,300) and ixed equipment ($20,900). The total interven-
tion period was 2 months with 25 actual days in the ield. 
Operational costs for this period were estimated at $44,200 
including $13,800 for staff and fuel, $6,800 for use of a sepa-
rate car by accompanying Ministry of Health staff, $8,900 for 
consumable reagents and other laboratory supplies, $6,400 for 
reference laboratory costs (supplies and wages), and $8,300 
for miscellaneous costs. The total cost associated with inter-
vening in the three districts was $88,400, of which half were 
ixed costs that would not be repeated until the unit or equip-
ment required repair or replacement. 
4.2  Mobile Laboratory use during an emergency 
carriage study 
Meningococcal conjugate vaccines will be available during 
the next few years for preventive vaccination of the popula-
tion of the meningitis belt. However, optimal immunization 
schedules and approaches (such as infant immunization, 
mass vaccination, catch-up campaigns, and booster doses) 
have not been deined. One of the primary missing pieces of 
data has been the degree of meningococcal carriage during an 
epidemic. These data are dificult to collect because of the 
unpredictable location and timing and frequent short duration 
of meningococcal epidemics in combination with the logistical 
dificulties of implementing a carriage study rapidly in 
impoverished and poorly accessible areas and before the im-
plementation of an emergency vaccine campaign (which may 
alter results). 
In February 2006, AMP and Centre Muraz (with funding 
from Sanoi-Pasteur) were notiied of a meningococcal sero-
group A epidemic in the Hauts-Bassins region of Burkina 
Faso. The study team was able to organize and implement, 
within two weeks of notiication, an evaluation of Nm and Sp 
carriage and seroprevalence in three villages located 60 km 
from Bobo-Dioulasso. The two Mobile Laboratories per-
formed initial processing of blood samples for serological 
analysis, including centrifugation and serum aliquoting. The 
Mobile Laboratories also performed initial microbiological 
processing of nasal swabs, including plate streaking and in-
cubation and preparation of swab suspensions. The Mobile 
Laboratories allowed processing of up to 110 specimens per 
day and eventual collection of the entire planned sample size 
of 624. Quality control of all equipment, including monitor-
ing of the refrigerator and incubator temperatures, was 
performed during the study and no deiciencies were found. 
In addition, cerebrospinal luid samples from meningitis 
Figure 7. Weekly number of suspected cases of acute bacterial 
meningitis in Nanoro, Zabré and Toma, 2004. 
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cases during the carriage study period could be prepared for 
culture analyses in the Mobile Laboratories. 
4.3 Mobile Laboratory use for technician training 
A secondary goal of the Mobile Laboratory is to provide 
ongoing and onsite training to laboratory technicians in 
district hospitals. During the 2004 evaluation of epidemics, 
technicians in the three intervention districts received train-
ing on bacteriological techniques. During May 2005, techni-
cians in ive district laboratories (Boussé, Gourcy, Manga, 
Pô, and Zabré) received training while during April 2006, 
technicians from three district laboratories (Boussé, Sapouy 
and Léo) received training. 
Training goals included review of storage and transport 
conditions of cerebrospinal luid specimens from health posts 
to district laboratories, evaluation of the use of trans-isolate 
media, performance of quality control of Gram staining, and 
identiication of critical issues such as reagent shortage. The 
Mobile Laboratory team identiied three broken microscopes, 
lack of incubators in all laboratories, lack of latex agglutina-
tion kits (necessary for serogroup determination and thus 
determination of the appropriate vaccine intervention), and 
poor cytology technique. During 2004, ive technicians 
received training in the Mobile Laboratory facilities followed 
by another ive during 2005 and nine during 2006. 
5 Discussion 
5.1 Epidemic intervention to guide vaccination 
We found that the epidemiology of acute bacterial meningitis 
epidemics differed substantially at the district level with one 
of the districts experiencing an outbreak of primarily Nm A, 
another primarily Nm W135 and the third a mix of NmW135 
and Sp. As a direct result of these indings, the Ministry of 
Health implemented trivalent A/C/W135 vaccine in Nanoro. 
In the absence of results from the Mobile Laboratory, a great-
er delay would have existed between notiication of the 
epidemic, conirmation of etiology, and vaccine response. In 
addition, some districts do not have adequate supplies or per-
sonnel to determine etiologic agents of disease during 
epidemics, potentially leading to use of an inappropriate 
vaccine or no vaccine response at all. 
The primary goal of the Mobile Laboratory is to provide 
information to allow appropriate epidemic response, including 
the need for and type of vaccine. During the irst year of im-
plementation, this goal met with partial success. Nanoro 
received trivalent A/C/W135 vaccine when they otherwise 
would have received bivalent A/C vaccine; nevertheless, the 
intervention occurred after the epidemic was subsiding. In 
Zabré and Toma results were obtained after the epidemic had 
begun to subside and thus no vaccination response was imple-
mented. These circumstances resulted partly from delays 
associated with implementing a new technology, such as 
stafing, training, and equipping the vehicle, and partly from 
having only one vehicle available. In addition, the Mobile 
Laboratory did not have the level of political support and inte-
gration into routine Ministry of Health activities that would 
allow for optimal use. In the future, the Mobile Laboratory 
should be prepared well in advance of the epidemic season 
and sent to the ield when the alert rather than the epidemic 
threshold is passed, activities that are more likely with political 
support from the Ministry of Health. 
5.2 Additional Mobile Laboratory benefits 
In addition to directing epidemic vaccine response, the Mobile 
Laboratory provides additional beneits. First, standard 
clinically-based case management strategies during the epi-
demic season call for treatment with one or two doses of oily 
chloramphenicol (6). Because this treatment is potentially 
inadequate for pneumococcal and Haemophilus inﬂuenzae 
type b meningitis, immediate provision of results to clinicians 
coupled with the availability of systemic ampicillin or ceftri-
axone may improve clinical outcome (7). Second, the Mobile 
Laboratory provides data on disease epidemiology in relatively 
remote districts. Our data, collected over a relatively short 
period in each District, suggest that the importance of various 
etiologic agents of disease changes over relatively short 
geographic areas and that Sp plays a substantial role in some 
areas. Third, Mobile Laboratory staff trained 19 local techni-
cians, who then provided ongoing data during the course of 
the epidemic. This is of particular importance in countries 
where rural and other MOH laboratory staff often receive 
little formal training. In theory, training does not need to rely 
on the existence of a Mobile Laboratory. However, the 
Mobile Laboratory creates eficiencies by conducting train-
ing at the same time as it assists with outbreak evaluation, 
allows technicians to receive training during an actual epi-
demic, and ensures that necessary equipment for training is 
available. Fourth, the Mobile Laboratory can be used to 
assess reagent stocks during an epidemic and to assist with 
replenishing them. Finally, the Mobile Laboratory was a crit-
ical tool in the successful implementation of a carriage study 
during the peak of a meningococcal serogroup A epidemic. 
This information will allow the development of models of 
how to use conjugate meningococcal vaccines and could not 
have been collected without the Mobile Laboratory. In gen-
eral, Mobile Laboratory technology may be useful for 
research by allowing studies during epidemics and in rural 
areas that otherwise do not have adequate laboratory facilities 
to process biological specimens. 
5.3 Mobile Laboratory cost 
The Mobile Laboratory allows the MOH to direct resources 
speciically to areas in epidemic without requiring that the 
entire country have adequate local diagnostic capability. 
Thus, the $88,400 cost of the Mobile Laboratory must be bal-
anced against the costs of strengthening and maintaining all 
district level laboratories in the country. For example, just the 
costs of purchasing 100 latex agglutination test kits per year 
for each of the approximately 55 districts in Burkina Faso 
will cost $82,500 based on a test price of $15. Because of the 
short shelf life of latex agglutination kits, this cost would be 
repeated each year. Also, this cost does not include staff, 
training, quality control, antibiotic resistance testing, and 
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other costs included in the Mobile Laboratory cost estimate. 
Other cost issues need to be taken into account. Each Mobile 
Laboratory can only intervene in one district per week, a 
clear limitation when multiple districts simultaneously pass 
the alert or epidemic threshold. Ideally, any particular coun-
try would maintain a leet of Mobile Laboratories suficient 
for most epidemic seasons. Also, once a Mobile Laboratory is 
purchased, and assuming it is well adapted to ield conditions 
in Africa, costs will be limited to the operational costs of the 
intervention (approximately $44,200 for three interventions) 
and system maintenance. 
5.4  Fixed vs. Mobile Laboratories 
In theory, the Mobile Laboratory should not be needed because 
district laboratories could perform all needed functions. In 
practice, though, this is unlikely to occur in the near future. 
Laboratories in some areas are not considered part of the 
Ministry of Health structure and thus may have no ixed bud-
get. There are an inadequate number of trained microbiologists 
and technicians to staff all district laboratories and lack of 
money for bringing staff to a central location for ongoing train-
ing. Finally, there is no manufacturing capacity in Africa for 
low-cost reagents adapted to conditions in the meningitis belt. 
Consequently, tests such as latex agglutination are expensive 
(in excess of US $10 per test) and frequently in short supply, 
past their expiration date, or poorly implemented. Because of 
these limitations, the epidemic response system used in much 
of the meningitis belt relies on shipment of cerebrospinal luid 
specimens from district to central laboratories. This process, 
however, is limited by the lack of transport media and vehicles 
for transportation. In Burkina Faso, for example, during 2003 
only an estimated 40% of districts in alert or epidemic sent the 
minimum required 15 CSF specimens. When specimens did 
arrive, 32% were contaminated (Burkina Faso MOH, unpub-
lished data, 2003). 
6 Conclusions and future directions 
This report demonstrates that in meningitis belt countries 
lacking adequate resources for nationwide laboratory 
improvement, the Mobile Laboratory can be successfully 
implemented to guide vaccine intervention and clinical 
management, expand knowledge of meningitis epidemiology 
and conduct studies in rural areas, and provide training to 
local technicians. Nevertheless, the impact of the Mobile 
Laboratory was not ideal. Future improvements should in-
clude costing, budgeting and programming the integration of 
the Mobile Laboratory into the national surveillance system 
to facilitate intervention when the alert rather than the 
epidemic threshold is passed. This integration may require a 
critical number of vehicles rather than just the two vehicles 
currently existing. This also would allow intervention in 
multiple districts simultaneously. The eficiency and beneit 
of the Mobile Laboratories could be improved as well by 
using them outside of the epidemic meningitis season for 
other activities such as use during the rainy season for evalu-
ation of diarrheal disease outbreaks and epidemiology. 
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Laboratoire mobile visant à améliorer la réponse  
à l’épidémie de méningite au Burkina Faso pendant  
la saison épidémique en 2004
R. T. Ouedraogo1, B.-M. Njanpop-Lafourcade2, P. Jaillard2, Y. Traoré3, J. E. Mueller2, J.-F. Aguilera2, 
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Résumé.  Un Laboratoire Mobile a été développé pour être utilisé essentiellement pendant la saison d’épidémie 
de méningite au Burkina Faso. Ce rapport décrit les caractéristiques du Laboratoire Mobile, son utilisation à ce 
jour, les problèmes rencontrés et leur résolution ainsi que les orientations futures. Au cours de l’année 2004, 
l’intervention du laboratoire mobile dans trois régions reculées du Burkina Faso où sévissait l’épidémie de 
méningite, a permis une prise en charge plus ciblée des cas et une campagne de vaccination dans l’une des 
régions. Toutefois, dans une autre région, l’intervention est survenue trop tard pour permettre la vaccination. En 
2006, le Laboratoire Mobile a été utilisé pour conduire une étude de portage d’urgence qui pour la première fois 
a été réalisée pendant le pic d’une épidémie de méningite à méningocoques du sérogroupe A. Ces informations 
sont cruciales pour l’élaboration des calendriers de vaccination par le vaccin antiméningococcique conjugué et 
des approches vaccinales. Pendant la période 2004-2006, le personnel du Laboratoire Mobile a formé des 
techniciens dans 11 laboratoires régionaux. De nombreux problèmes ont été identiiés sur le prototype initial du 
laboratoire, par exemple une production insufisante d’énergie par les piles solaires pour alimenter le réfrigérateur 
et l’incubateur ain de maintenir des températures appropriées et le fait d’avoir une seule unité intégrée qui 
nécessitait l’utilisation d’un véhicule distinct pour le transport des prélèvements. En 2005-2006, un second 
laboratoire a été développé qui utilisait un générateur ou une source d’énergie locale pour l’alimentation et qui 
incluait un laboratoire qui pouvait être séparé du véhicule. Actuellement, la limite principale du Laboratoire 
Mobile est qu’il n’a pas été intégré dans les activités régulières du ministère de la Santé, son utilisation étant 
limitée à la fois pendant et entre les saisons de méningite.
Référence. Ouedraogo, R. T., Njanpop-Lafourcade, B.-M., Jaillard, P., Traoré, Y., Mueller, J. E., Aguilera, 
J.-F., Dabal, M., Tiendrébéogo, S. R., Goehde, W., da Silva, A., Gessner, B. D., and Stoeckel, P.: Mobile 
laboratory to improve response to meningitis epidemics, Burkina Faso epidemic season 2004, Field Actions 
Science Report. 
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Laboratorio móvil para mejorar la respuesta  
de las epidemias de meningitis, temporada  
epidémica 2004 de Burkina Faso
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Resumen. Para utilizarlo sobre todo durante la temporada epidémica de meningitis en Burkina Faso, se ha 
desarrollado un laboratorio móvil. Aquí se describen sus características, su utilización hasta la fecha, los 
problemas y soluciones experimentados, así como las direcciones futuras. Durante 2004, gracias a la inter-
vención con laboratorio móvil desarrollada en tres provincias remotas de Burkina Faso con epidemias de 
meningitis, se logró una gestión más centralizada y la vacunación directa en una provincia. El retraso de la 
intervención impidió la aplicación de vacunas en una segunda provincia. Durante 2006, se utilizó el labora-
torio móvil para estudiar los transportes de emergencia que por primera vez tenía lugar durante el brote 
epidemiológico de serotipo de meningococo A. Ello es esencial para el diseño y enfoque de los programas de 
vacunas meningocócicas conjugadas. Durante 2004/06, diversos técnicos de 11 laboratorios provinciales 
fueron formados por el personal del laboratorio móvil. Se identiicaron muchos problemas con el prototipo 
inicial, como, la imposibilidad de producir energía solar suiciente para mantener una temperatura adecuada 
en el frigoríico y la incubadora y la disposición de una única unidad integrada que necesitaba el uso de un 
vehículo independiente para transportar las muestras. Durante 2005/06 se desarrolló otro laboratorio que 
podía separarse del vehículo que lo integraba. Actualmente la principal limitación radica en la falta de inte-
gración con el Ministerio de Sanidad, por lo que su uso queda restringido a los periodos durante y entre las 
temporadas de meningitis.
Referencia. Ouedraogo, R. T., Njanpop-Lafourcade, B.-M., Jaillard, P., Traoré, Y., Mueller, J. E., Aguilera, 
J.-F., Dabal, M., Tiendrébéogo, S. R., Goehde, W., da Silva, A., Gessner, B. D., and Stoeckel, P.: Mobile 
laboratory to improve response to meningitis epidemics, Burkina Faso epidemic season 2004, Field Actions 
Science Report. 
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